Efficacy of berberine in patients with non-alcoholic fatty liver disease

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Yan, Hong Mei ^a   Xia, Ming Feng ^a   Wang, Yan ^b   Chang, Xin Xia ^a   Yao, Xiu Zhong ^a   Rao, Sheng Xiang ^a   Zeng, Meng Su ^a   Tu, Yin Fang ^c   Feng, Ru ^b   Jia, Wei Ping ^c   Liu, Jun ^a   Deng, Wei ^a   Jiang, Jian Dong ^b   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BERBERINE; DRUG METABOLITE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MESSENGER RNA; PIOGLITAZONE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BROWN ADIPOSE TISSUE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPT 1 ALPHA GENE; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENERGY METABOLISM; EPIDIDYMIS FAT; FAT CONTENT; FATIGUE; FEMALE; FRACTURE; GCK GENE; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART DISEASE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LDLR GENE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER METABOLISM; LIVER TOXICITY; LIVER WEIGHT; LPK GENE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MTTP GENE; MULTICENTER STUDY; MYALGIA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OPEN STUDY; PARALLEL DESIGN; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE DRUG DOSE; STOMACH DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; UPSET STOMACH; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ANIMAL; BLOOD; BODY WEIGHT; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIPID DIET; LIVER; METABOLISM; METABOLOME; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ADIPOSITY; ADMINISTRATION, ORAL; ANIMALS; BERBERINE; BLOOD GLUCOSE; BODY WEIGHT; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER; MALE; METABOLOME; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84942317017     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134172     Document Type: Article

References (33)

1. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48(Suppl 1): S104-12. doi: 10.1016/j.jhep.2008.01.009 PMID: 18304679
2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. PMID: 16447287
3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10:330-44. doi: 10.1038/nrgastro.2013.41 PMID: 23507799
4. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009; 104:861-67. doi: 10.1038/ajg.2009.67 PMID: 19293782
5. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355:2297-307. PMID: 17135584
6. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med; 362:1675-85. doi: 10.1056/NEJMoa0907929 PMID: 20427778
7. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135:1176-84. doi: 10.1053/j.gastro.2008.06.047 PMID: 18718471
8. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism.2008; 57:712-7. doi: 10.1016/j.metabol.2008.01.013 PMID: 18442638
9. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004; 10: 1344-51. PMID: 15531889
10. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008; 201: 266-73. doi: 10.1016/j.atherosclerosis.2008.02.004 PMID: 18355829
11. Lu SS, Yu YL, Zhu HJ, Liu XD, Liu L, Liu YW, et al. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. Journal of Endocrinology. 2009; 200:159-65. doi: 10.1677/JOE-08-0419 PMID: 18996945
12. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism: Clinical and Experimental. 2009; 58:109-19.
13. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008; 93:2559-65. doi: 10.1210/jc.2007-2404 PMID: 18397984
14. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.Nature. 2014; 510:84-91. doi: 10.1038/nature13478 PMID: 24899308
15. Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D, et al. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Rese. 2010; 51: 2504-15.
16. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288:E462-8. PMID: 15339742
17. Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007; 22:775-7. PMID: 17565629
18. Cho E. Berberini hydrochloride. in Pharmacopoeia of the People's Republic of China 2, 1990;437-439.
19. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012; 36:843-54.
20. Tan XS, Ma JY, Feng R, Ma C, Chen WJ, Sun YP, et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One. 2013;31; 8:e77969. doi: 10.1371/journal.pone.0077969 PMID: 24205048
21. Bian H, Yan H, Zeng M, Rao S, Yao X, Zhou J, et al. Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. Diabetes Technol. Ther. 2011; 13: 149-55. doi: 10.1089/dia.2010.0101 PMID: 21284482
22. Ma JY, Feng R, Tan XS, Ma C, Shou JW, Fu J, et al. Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci. 2013; 102:4181-92. doi: 10.1002/jps.23718 PMID: 24006193
23. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355:2297-307. PMID: 17135584
24. Takihata M, Nakamura A, Tajima K, Inazumi T, Komatsu Y, Tamura H, et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013; 15:455-62. doi: 10.1111/dom.12055 PMID: 23279373
25. Chen W, Miao YQ, Fan DJ, Yang SS, Lin X, Meng LK, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. Aaps Pharmscitech 2011; 12: 705-11. doi: 10.1208/s12249-011-9632-z PMID: 21637946
26. Hua W, Ding L, Chen Y, Gong B, He J, Xu G. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal. 2007; 44:931-7. PMID: 17531424
27. Xie W, Gu D, Li J, Cui K, Zhang Y. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One. 2011; 6:e24520. doi: 10.1371/journal.pone.0024520 PMID: 21915347
28. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010; 38:1779-84. doi: 10.1124/dmd.110.033936 PMID: 20634337
29. Liu J, Huang X, Xue M, Jiang Z, Zhang L, Ma S. Tissue distribution of 4 alkaloids of Compound Matrine Injection in rats. Pharmacology and Clinics of Chinese Materia Medica. 2011; 27: 74-8.
30. Lee K, Kerner J, Hoppel CL. Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex. J Biol Chem. 2011; 286:25655-62. doi: 10.1074/jbc.M111.228692 PMID: 21622568
31. Reiling E, van 't Riet E, Groenewoud MJ, Welschen LM, van Hove EC, Nijpels G, et al. Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk. Diabetologia. 2009; 52:1866-70. doi: 10.1007/s00125-009-1413-9 PMID: 19533084
32. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006; 55:2256-64. PMID: 16873688
33. Li H, Wang X, Mao Y, Hu R, Xu W, Lei Z, et al. Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK. Cardiovasc Diabetol. 2014; 13:24. doi: 10.1186/1475-2840-13-24 PMID: 24447392